Document is current
Any future updates will be listed below
-
Authors
Grootaert, Mandy O. J.
Pasut, Alessandra
Raman, Jana
Simmonds, Steven J.
Callewaert, Bram
Col, Ümare
Dewerchin, Mieke
Carmeliet, Peter
Heymans, Stephane
Jones, Elizabeth A. V.
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (G0B5920N, G0B5920N, G0B5920N, G0B5920N, G0B5920N)
European Research Area Network on Cardiovascular Diseases (ENRICH, ENRICH, ENRICH)
Horizon 2020 Framework Programme (848109, 848109, 848109, 848109, 848109)
- License Information
-
More Information
Article History
Received: 18 November 2024
Accepted: 29 January 2025
First Online: 7 February 2025
Declarations
:
: All animal experiments were approved by the local ethics committee of KU Leuven (Project 116/2021).
: Not applicable.
: SH receives personal fees for independent scientific advice on early development in the field of heart failure from AstraZeneca, Ribocure, and CSL Behring, and receives research support from AstraZeneca and CSL Behring.
